A Diabetes Drug Cut Breast Cancer Risk by 30% in New Data
A University of Pennsylvania study found women on GLP-1 medications had 30.5% lower breast cancer incidence. Here's what the data actually shows.
What a Large Health Records Study Found About GLP-1 Drugs and Breast Cancer
GLP-1 medications — the class that includes semaglutide, sold under the brand names Ozempic and Wegovy — have spent the last few years moving well beyond their original purpose. Developed first as a treatment for type 2 diabetes, they are now prescribed widely for weight loss, and researchers are actively studying whether they may also have a role in conditions ranging from sleep apnea to addiction. The latest area drawing serious attention: breast cancer prevention.
A study from the University of Pennsylvania, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and published June 2 in JCO Oncology Practice, found that women taking GLP-1 medications were approximately 30% less likely to be diagnosed with breast cancer compared to women who were not taking them. The data comes from a large pool of real-world health records, not a clinical trial, which shapes both its strengths and its limits.
How the Study Was Structured
The research team drew from electronic health records across the University of Pennsylvania Health System, which covers both academic and community medical sites in Pennsylvania and New Jersey. From an initial pool of 217,624 females who had breast imaging between January 1, 2022 and June 30, 2025, they narrowed the focus to 111,646 women between the ages of 45 and 80 who were overweight or obese — defined as a BMI of 25 or higher — and had documented breast imaging outcomes on file.
Of that group, 15,264 women, or 13.7%, had been prescribed GLP-1 medications before their imaging appointment. The remaining 96,382 women, representing 86.3% of the cohort, had no record of GLP-1 use. Because the two groups could differ in ways that independently affect cancer risk, the researchers used a one-to-one matching process. Each woman on a GLP-1 drug was paired with a woman not on the drug, matched for age, race, ethnicity, BMI, breast density, and diabetes status. The goal was to isolate whether GLP-1 exposure itself — not these background factors — was associated with different cancer rates.
The primary outcome was new breast cancer diagnoses recorded during the study window.
The Numbers Behind the Finding
Among the 15,264 women taking GLP-1 medications, 1.62% were diagnosed with breast cancer during the study period. Among the 96,382 women not using these drugs, the diagnosis rate was 2.47%. That difference translates to an absolute risk reduction of approximately 0.69 percentage points — modest in absolute terms, but statistically meaningful across a dataset this size.
In the full, unmatched cohort, the association was slightly stronger: GLP-1 use was linked to roughly 35% lower odds of a breast cancer diagnosis. Once the researchers controlled for confounding variables through matching, that figure settled at a 30.5% reduction in breast cancer incidence. The protective pattern held across racial groups — including Black and white women — and was independent of diabetes status, age, BMI, and breast density.
That consistency across subgroups matters. It makes it harder to dismiss the finding as a side effect of one particular demographic or health profile within the sample.
Why GLP-1 Drugs Might Affect Cancer Risk
The mechanisms are not fully understood, but researchers have identified several plausible pathways. GLP-1 drugs promote weight loss, and excess body weight is a well-established risk factor for breast cancer, particularly in postmenopausal women. Adipose tissue produces estrogen, and higher estrogen levels are linked to certain types of breast cancer. Reducing body fat through any method would be expected to lower that hormonal contribution to risk.
Beyond weight, GLP-1 drugs appear to reduce systemic inflammation — a process that has long been associated with cancer development across multiple tumor types. Chronic low-grade inflammation can promote the kind of cellular environment in which abnormal growth accelerates and goes undetected by the immune system for longer. If GLP-1 medications dampen that inflammatory background, that alone could meaningfully shift cancer probability over time.
There is also early laboratory evidence suggesting GLP-1 receptor agonists may act more directly on cancer biology itself. Studies conducted outside of living subjects have indicated these drugs may inhibit cancer cell activity, though translating that finding to human outcomes requires considerably more investigation. At this stage, it remains a hypothesis worth testing, not a confirmed mechanism.
The combination of metabolic improvement, inflammation reduction, and possible direct cellular effects gives researchers multiple angles to pursue. Whether one pathway dominates or all three contribute is something future research will need to sort out.
What This Study Cannot Tell Us
Retrospective cohort studies are built from records generated for other purposes — in this case, routine clinical care. That design makes it possible to study large populations efficiently and observe real-world patterns, but it also means the researchers cannot fully rule out every variable that might influence the outcome. Women who are prescribed GLP-1 medications may be more engaged with their healthcare overall, more likely to undergo regular screening, or more health-conscious in other ways that the matching process did not fully capture.
This is not a clinical trial where participants were randomly assigned to take a drug or a placebo. That randomization is the gold standard for establishing causation. What this study shows is a strong association — a pattern worth taking seriously, but not yet sufficient grounds to recommend GLP-1 medications specifically for breast cancer prevention. The researchers themselves are clear on that point.
More studies, ideally including prospective designs that follow women forward in time, are needed before the picture sharpens enough to guide clinical decision-making.
Where This Leaves Prevention Today
Regular breast cancer screening and established lifestyle factors — maintaining a healthy weight, limiting alcohol intake, staying physically active — remain the foundation of risk reduction for women at elevated risk. No single drug finding, however promising, replaces that foundation.
GLP-1 medications carry their own side effect profiles, costs, and access considerations that matter for any conversation about using them beyond their existing approved indications. Semaglutide-based drugs are expensive without insurance coverage, and supply constraints have intermittently affected availability since demand surged. Any discussion about expanding their use to oncology prevention would need to account for those realities alongside the emerging biological evidence.
What this University of Pennsylvania study does, most usefully, is give researchers a more focused question to answer: Is the association replicable in other health systems, with different populations, over longer follow-up periods? A 30.5% reduction in incidence, if it holds under closer scrutiny, would be a clinically significant finding in a disease that affects roughly one in eight women in the United States over a lifetime.
The absolute risk numbers from this study — 1.62% versus 2.47% — are a useful anchor for that conversation.
This article is for general informational purposes only and does not constitute medical advice. Drug availability, pricing, and clinical guidelines change frequently. Consult a qualified healthcare provider before making any decisions about medications or cancer screening.